Impact Biomedical Inc. issued a corrected press release stating that the exchange ratio for its proposed merger with Zoar Limited is one Zoar share for each Impact Common Stock share held immediately before the merger, after giving effect to a 1-for-12.62 reverse stock split. The correction replaces an earlier 1-for-4 ratio. The split will take effect at 12:01 a.m. Eastern time on September 23, 2026, with Impact continuing to trade on the NYSE American under ticker IBO and receiving a new CUSIP number. Shares outstanding are expected to fall from approximately 107,821,231 to 8,543,679, subject to rounding. The proposed merger is expected to create a pharmaceutical company focused on active pharmaceutical ingredients and intermediates for special therapeutic treatment areas, but the split does not ensure continued NYSE American compliance, listing approval or completion of the transaction.